Received Apr 27, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Adult product administered to child; Engerix-B extra dose in child series, underage dose and late dose; Extra dose administered; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 18-year-old patient who received HBV (Engerix B adult) for prophylaxis. Previously administered products included Engerix-B (4 doses of Engerix-B series as a child). In NOV-2025, the patient received Engerix B adult. In NOV-2025, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: Adult product administered to child), overdose (Verbatim: Engerix-B extra dose in child series, underage dose and late dose) and extra dose administered (Verbatim: Extra dose administered). The outcome of the adult product administered to child, overdose and extra dose administered were not applicable. Additional Information: GSK receipt date: 16-APR-2026 Registered Nurse inquired whether a patient who was 18 years and 10 months old could receive an adult dose of Engerix-B vaccine. A different medical provider administered an adult dose of Engerix-B to the patient. The batch number was not provided, and unable to contact the reporter.